Results
|
|
1.
|
|
|
|
2.
|
|
|
|
3.
|
|
|
|
4.
|
|
|
|
5.
|
|
|
|
6.
|
|
|
|
7.
|
|
|
|
8.
|
|
|
|
9.
|
|
|
|
10.
|
|
|
|
11.
|
|
|
|
12.
|
|
|
|
13.
|
Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. [electronic resource] by
- Pohl, Michael
- Stricker, I
- Schoeneck, A
- Schulmann, K
- Klein-Scory, S
- Schwarte-Waldhoff, I
- Hasmann, M
- Tannapfel, A
- Schmiegel, W
- Reinacher-Schick, A
Producer: 20090910
In:
Journal of cancer research and clinical oncology vol. 135
Availability: No items available.
|
|
|
14.
|
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. [electronic resource] by
- Henjes, F
- Bender, C
- von der Heyde, S
- Braun, L
- Mannsperger, H A
- Schmidt, C
- Wiemann, S
- Hasmann, M
- Aulmann, S
- Beissbarth, T
- Korf, U
Producer: 20130404
In:
Oncogenesis vol. 1
Availability: No items available.
|
|
|
15.
|
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. [electronic resource] by
- Sims, A H
- Zweemer, A J M
- Nagumo, Y
- Faratian, D
- Muir, M
- Dodds, M
- Um, I
- Kay, C
- Hasmann, M
- Harrison, D J
- Langdon, S P
Producer: 20120723
In:
British journal of cancer vol. 106
Availability: No items available.
|
|
|
16.
|
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. [electronic resource] by
- Bartsch, R
- Frings, S
- Marty, M
- Awada, A
- Berghoff, A S
- Conte, P
- Dickin, S
- Enzmann, H
- Gnant, M
- Hasmann, M
- Hendriks, H R
- Llombart, A
- Massacesi, C
- von Minckwitz, G
- Penault-Llorca, F
- Scaltriti, M
- Yarden, Y
- Zwierzina, H
- Zielinski, C C
Producer: 20141121
In:
Annals of oncology : official journal of the European Society for Medical Oncology vol. 25
Availability: No items available.
|